Who
Todd Watanabe
Director and Officer
Company insider
Files Form 4 as: President and CEO, Arcutis Biotherapeutics.
In numbers
- Trades disclosed
- 167
- Buys
- 3
- Sells
- 66
- Bought
- $31K
- Sold
- $11.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Feb 2020
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $114K4,375 at $26.12 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $114K4,375 at $26.12 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $75K3,172 at $23.61 | filing |
| 4 May 2026filed 6 May 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $75K3,172 at $23.61 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $913K36,281 at $25.16 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $28K1,068 at $25.91 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $913K36,281 at $25.16 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $28K1,068 at $25.91 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —102,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —266,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —266,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —102,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $506K19,833 at $25.50 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $506K19,833 at $25.50 | filing |
| 24 Nov 2025filed 24 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M48,945 at $30.36 | filing |
| 21 Nov 2025filed 24 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $32K1,055 at $30.00 | filing |
| 3 Nov 2025filed 5 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $284K11,478 at $24.71 | filing |
| 3 Nov 2025filed 5 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1,75369 at $25.40 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M40,000 at $25.03 | filing |
| 2 Oct 2025filed 3 Oct 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $416K20,739 at $20.04 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Todd Watanabe; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.